Kailera Therapeutics, Inc.’s Lock-Up Period Set To Expire Tomorrow (NASDAQ:KLRA)

Kailera Therapeutics’ (NASDAQ:KLRA) lock-up period is set to expire on Wednesday, October 14th. Kailera Therapeutics had issued 39,062,500 shares in its IPO on April 17th. The total size of the offering was $625,000,000 based on an initial share price of $16.00. After the end of Kailera Therapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Kailera Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kailera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Down 2.4%

Shares of NASDAQ:KLRA opened at $11.33 on Tuesday. The stock has a market cap of $1.47 billion and a P/E ratio of -0.00. Kailera Therapeutics has a twelve month low of $9.76 and a twelve month high of $28.23. The business’s 50 day moving average is $14.92.

Kailera Therapeutics (NASDAQ:KLRA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, equities research analysts expect that Kailera Therapeutics will post -3.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Tidal Investments LLC purchased a new position in Kailera Therapeutics in the second quarter valued at about $309,000. Squarepoint Ops LLC acquired a new position in Kailera Therapeutics during the 2nd quarter worth $993,000. Mirador Capital Partners LP acquired a new position in Kailera Therapeutics during the 3rd quarter valued at about $666,000. State Street Corp acquired a new stake in Kailera Therapeutics in the 2nd quarter valued at about $19,126,000. Finally, Frazier Life Sciences Management L.P. bought a new position in shares of Kailera Therapeutics in the second quarter valued at $24,233,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.